What are the main challenges Pfizer is currently facing?

Pfizer is facing patent expirations on several blockbuster drugs and a sharp decline in sales of its Covid products.

How were Pfizer's Q1 2026 results?

Pfizer reported better-than-expected Q1 2026 results, but exact figures have not been disclosed yet.

Did Pfizer provide financial guidance for the current year?

Pfizer did not provide specific guidance for Q2 or the current fiscal year, focusing instead on long-term expectations through 2029.

Pfizer CEO Sees Return to Growth by 2029

Q: When does Pfizer expect to return to consistent growth?

Pfizer expects to return to consistent growth by 2029, with high-single-digit average annual growth through 2033.

Pfizer CEO Albert Bourla said the company expects to return to consistent growth by 2029, with high-single-digit average annual revenue growth from 2029 through 2033, after overcoming challenges from patent expirations and the decline of its Covid business.

Pfizer (NYSE: PFE) CEO Albert Bourla said the company expects to return to consistent growth by 2029, with high-single-digit average annual revenue growth from 2029 through 2033, after overcoming challenges from patent expirations on blockbuster drugs and the sharp decline of its Covid franchise.

Bourla's comments came after Pfizer reported better-than-expected first-quarter results for 2026. "Products are losing patents, and we have a clear line of sight on growth starting in '29," Bourla said in an interview.

Key Financial Results

Metric	Q1 2026	YoY Change
Revenue	Not yet disclosed	Better than expected
Net Income	Not yet disclosed	—
EPS	Not yet disclosed	—

Note: Exact figures have not been released.

Key Takeaways

Bourla acknowledged the significant headwinds from patent expirations on several top-selling drugs and the steep decline in Covid-related sales. However, he expressed confidence in Pfizer's pipeline and ability to drive growth starting in 2029.

Future Guidance

Pfizer expects high-single-digit average annual revenue growth (7% to 9%) from 2029 to 2033. No specific guidance was provided for Q2 or the current fiscal year.

Stock Impact

Pfizer shares (PFE) showed little movement following the announcement, as investors await more details on the growth strategy and how the company will replace revenue lost to patent expirations.

What This Means for Investors

Bourla's remarks indicate that Pfizer is in a challenging transition period but has a clear medium-term recovery plan. Investors should monitor the company's progress in developing new drugs, offsetting Covid revenue declines, and potential acquisitions.